Y-27632 dihydrochloride [129830-38-2]
Y-27632 dihydrochloride (CAS 129830-38-2) is a small-molecule inhibitor targeting ROCK kinases (Rho-associated protein kinases), specifically interacting with the catalytic domains of ROCK-1 and ROCK-2. It inhibits their kinase activity with an IC50 of approximately 140 nM. By targeting ROCK signaling, Y-27632 disrupts Rho-mediated formation of cellular stress fibers, influences cell cycle progression from G1 to S phase, and interferes with cytokinesis. It is commonly utilized in studies investigating cell proliferation, cytoskeletal organization, and stem cell viability.
References
1. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. T Ishizaki, M Uehata, I Tamechika, J Keel Molecular Pharmacology 2000
2. A ROCK inhibitor permits survival of dissociated human embryonic stem cells K Watanabe, M Ueno, D Kamiya, A Nishiyama. Nature Biotechnology. 2007
- 1. Swagata Goswami, Qiming Zhang, et al. "Ceramide synthesis mediates colorectal cancer metastasis through a YAP-driven regenerative program." Science. 2026 Sep 24;393(6818):eadw8520. PMID: 42784694
- 2. Nan Jiang, Yingying Xue, et al. "Biohybrid Organoid-Robot Sensing for Olfaction Intelligence." Biosens Bioelectron. 2026 Aug 8:313:119107. PMID: 42580226
- 3. Saori Goto, Vikram Deshpande, et al. "Lineage plasticity driven by GATA6 loss fuels colorectal cancer metastasis." Cell Stem Cell. 2026 Jun 22:S1934-5909(26)00205-5. PMID: 42330962
- 4. Shichao Li, Ting Gao, et al. "Rationally designed light-inducible RNA-releasing protein for translational regulation and optogenetic control of gene therapies." Trends Biotechnol. 2026 Apr 8:S0167-7799(26)00089-2. PMID: 41956945
- 5. Tianyu Tao, Xianming Feng, et al. "The lncRNA DAMER selectively guides m6A-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer." Nat Cell Biol. 2026 Apr;28(4):797-811. PMID: 41792266
- 6. Jun Zhao, Xiaoying Zhang, et al. "Generation of two induced pluripotent stem cell (iPSC) lines (HZSMHCI001-A and HZSMHCI004-A) from a mother–child dyad with major depressive disorder and …." Stem Cell Research Volume 91, March 2026, 103920. PMID: 41643482
| Physical Appearance | A solid |
| Storage | Desiccate at 4°C or below |
| M.Wt | 320.26 |
| Cas No. | 129830-38-2 |
| Formula | C14H21N3O·2HCl |
| Synonyms | y-27632, Y27632, Y-27632 dihydrochloride, Y 27632 |
| Solubility | ≥111.2 mg/mL in DMSO; ≥17.57 mg/mL in EtOH; ≥52.9 mg/mL in H2O |
| Chemical Name | 4-[(1R)-1-aminoethyl]-N-pyridin-4-ylcyclohexane-1-carboxamide |
| Canonical SMILES | O=C([C@@H]1CC[C@]([C@H](N)C)(00)CC1)NC2=CC=NC=C2.00Cl.00Cl |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
| Cell lines | Human (hu) and rat(r) prostatic smooth mus-cle cells (PSM) |
| Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
| Reaction Conditions | 24h and 48 h; 100 μM |
| Applications | After identifying prostatic smooth muscle cells and confirming the expression of Rho-kinase in these cells we investigated whether the Rho-kinase inhibitor Y-27632 affected the viability and proliferation of these cells. In serum-free medium huPSM and rPSM were made quiescent for 24 hours. Cell viability using neutral red and MTT assays was assessed 24 and 48 hours after stimulating the cells with 1% serum in the absence and presence of Y-27632 (0.01 to 100 μM). The results of these assays showed that the number of the cells increased between the 24- and 48-hour incubation periods after re-stimulation with 1% serum. However, in the presence of Y-27632 the increase in the number of live cells was less than in the control group. This effect was concentration dependent. |
| Animal experiment [2]: | |
| Animal models | Adult Swiss male albino mice |
| Dosage form | 0.1 mg/kg/day; intrapertoneal injection |
| Applications | The drug was tested by histopathological examination showed that Y-27632 administration to EAC-bearing mice diminished pathological structure, to 60–70% degree, toward to normal intact histological structure especially in pre-carcinoma inoculation regime. Respect to this, ROCK inhibition by Y-27632 decreased significantly tumor invasion and metastasis. Our immunohistochemistry results showed that ROCK2 was mainly inhibited by Y-27632 in pre-carcinoma, but not in post-carcinoma, groups. |
| Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| References: [1] Rees R W, Foxwell N A, Ralph D J, et al. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells[J]. The Journal of urology, 2003, 170(6): 2517-2522. [2] Isler D, Ozaslan M, Karagoz I D, et al. Antitumoral effect of a selective Rho-kinase inhibitor Y-27632 against Ehrlich ascites carcinoma in mice[J]. Pharmacological Reports, 2014, 66(1): 114-120. | |
| Description | Y-27632 is a selective inhibitor of ROCK1 (p160ROCK) with Ki of 140 nM, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK. | |||||
| Targets | ROCK1 | ROCK2 | ||||
| IC50 | 140 nM (Ki) | 300 nM (Ki) | ||||
Quality Control & MSDS
- View current batch:
